Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Sustained improvement in survival for primary ocular adnexal lymphoma from 2005 to 2024 by model-based period analysis.

Created on 25 Jun 2026

Authors

Jing Zeng, Xianfen Cao, Xi Yin, Qing Zhou, Jun Lyu, Xiangyin Sha

Published in

Discover oncology. Jun 25, 2026. Epub Jun 25, 2026.

Abstract

Primary ocular adnexal lymphoma (POAL) is the most common malignancy affecting para-ocular tissues, making prognosis and survival critical concerns. This study analyzed trends in five-year relative survival rates (RSR) to evaluate survival outcomes.
This retrospective study included patients diagnosed with POAL from the Surveillance, Epidemiology, and End Results database. Five-year RSR was calculated for the periods 2005-2009, 2010-2014, and 2015-2019. Data were stratified by demographic and clinical characteristics. Model-based period analysis was conducted to assess RSR trends and project RSR for 2020-2024.
The five-year RSR for POAL patients increased from 96.1% to 99.1% between 2005 and 2019, with projections suggesting continued favorable trends. RSR decreased with advancing age but improved across all age groups; for 2020-2024, RSR was projected to approach 100% for patients aged < 50 and 50-69 years, and 98.3% for those ≥ 70 years. Females consistently showed slightly higher RSR than males. White patients demonstrated steady improvement, while Black patients exhibited a fluctuating trend and other racial groups showed modest increases. Higher RSR was observed in patients with conjunctival involvement, unilateral disease, and mucosal-associated lymphoid tissue (MALT) or follicular lymphoma subtypes.
Survival for POAL patients improved between 2005 and 2019. Projected estimates for 2020-2024, while subject to inherent uncertainty, suggest continued favorable outcomes, providing useful prognostic information for clinicians and patients.

PMID:
42347900
Bibliographic data and abstract were imported from PubMed on 25 Jun 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement